Breaking News, Promotions & Moves

Asahi Kasei Bioprocess America Names New President

Chris Rombach brings 30+ years of experience in leadership and sales management within the biopharmaceutical sector to the role.

Chris Rombach.

Asahi Kasei Bioprocess America Inc. (AKBA), a provider of advanced filtration and fluid management solutions for the biopharmaceutical industry, has appointed Chris Rombach as its President.

Rombach, who previously served as Executive Vice President and Head of Fluid Management, brings over 30 years of experience in leadership and sales management within the biopharmaceutical sector.

Throughout his career, he has contributed to advancing bioprocessing systems, including serving as a founding member of the Bio-Process Systems Alliance (BPSA) and pioneering the adoption of single-use systems. Since joining the company five years ago, Rombach has led commercial growth functions. While many companies focused on solutions related to the COVID-19 pandemic, Rombach elected to pursue the Oligosynthesis market to establish AKBA as a key player in the process.  That work, coupled with a focus on promoting their MOTIV buffer formulation system, helped fuel a strong growth trajectory.

“I am honored and excited to step into the role of President at AKBA,” said Rombach. “Together, we will pursue new challenges, foster ideas for our stakeholders, and drive our vision forward. Most importantly, we will continue to build a brighter future for our team, our community, and, of course, our wonderful customers, creating an experience that is truly ‘Built for You.'”

Under Rombach’s leadership, AKBA aims to strengthen its commitment to delivering forward-thinking solutions that enhance safety and efficiency in biologics manufacturing. The company will continue helping customers solve purity challenges in their development processes. Rombach will also support business entities, including human resources and finance.

“Chris’ deep industry expertise, passion for innovation, and unwavering commitment to our customers make him the ideal leader to take AKBA into the future,” said Yusuke Kanazawa, Head Asahi Kasei’s Bioprocess Division. “We are confident that his vision will drive continued growth and success for our organization and partners.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters